First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Adjournment of Annual Meeting
17 déc. 2021 09h06 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio
16 nov. 2021 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI), (“First Wave BioPharma,” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
28 sept. 2021 08h00 HE | First Wave BioPharma, Inc.
Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
21 sept. 2021 12h47 HE | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
13 sept. 2021 06h00 HE | AzurRx BioPharma, Inc.
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to GI...